Correction

Correction: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study

Anna-Mária Tőkés¹, Janina Kulka¹, Sándor Paku², Ágnes Szik¹, Csilla Páska¹, Pál Kaposi Novák¹, László Szilák¹, András Kiss¹, Krisztina Bögi¹ and Zsuzsa Schaff¹

Corresponding author: Janina Kulka, kj@korb2.sote.hu

Published: 11 May 2005

Breast Cancer Research 2005, 7:162 (DOI 10.1186/bcr1265)

This article is online at http://breast-cancer-research.com/content/7/4/162 © 2005 Tőkés *et al.*, licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited

After publication of this work [1], it was brought to our attention that two corrections were required in the first table. First, the Claudin 1 forward and reverse primer sequences were the same. Second, the forward and reverse primer sequences of GAPDH were inversed.

The correct sequences can be found in Table 1.

Table 1

The CLDN1, CLDN3, CLDN4 and GAPDH primer sequences, position and product size								
Primer	Forward			Reverse			Product size (bp)	GI number
	Sequence 5'-3'	Position (bp)		Sequence 5'-3'	Position (bp)			
CLDN1	gcgcgatatttcttcttgcagg	378-399	22	ttcgtacctggcattgactgg	470-490	21	112	4559277
GAPDH	gaaggtgaaggtcggagt	81-98	20	gaagatggtgatggatttc	287-306	18	225	7669491

bp, base pairs; CLDN, claudin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Reference

¹2nd Department of Pathology, Semmelweis University, Budapest, Hungary

²Department of Molecular Pathology, Joint Research Organization of the Hungarian Academy of Sciences, Budapest, Hungary

Tőkés A-M, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005, 7:R296-R305.